

FOR PARTNERS · パートナーの皆さまへ

Europe runs on our light. Japan starts with its first partners.

Precisely dosed red and near-infrared light for female health and longevity — running in 17 systems across 5 countries. We are choosing the partners who open Japan with us.

光のバイオテクノロジーで、女性のエイジングに向き合います。日本での最初のパートナーを求めています。

17

systems in 5 countries

13,000+

sessions logged

5,000+

home devices sold

3

ways in

● In Japan 2–10 Oct 2026

● Osaka · Yokohama · Tokyo

PARTNERS



LE GRAND BELLEVUE



Luminous Labs FlexCo · Graz, Austria · founded 2021 · luminouslabs.health · September 2026

SUPPORTED BY

Funded by the
European Union

A platform already proven in Europe, looking for the partners who take it into Japan.

Whether you operate venues, build products, run research or invest — there is a concrete first step, and it starts in October.

ウェルネス施設、製品への組み込み、共同研究、戦略投資——それぞれに具体的な第一歩があります。

01 It is running, not a prototype

17 Redgevity Master systems in 5 countries, 13,000+ logged sessions and 5,000+ home devices sold. Revenue grew 2.6x from 2024 to 2025.

02 It is built on dose, not on power

OptimalDose™ sets and caps each programme; a fixed position keeps the distance — and so the dose — the same every time.

03 It comes with serious partners

Biogena (investor, co-developer, operator; listed in Vienna, Sep 2026), fertility clinics KIWI and Fertisuisse, Politecnico di Milano.

04 Japan is where it matters most

The most-aged society: women live 11.6 years with limits, and ¥1.9 tn is lost every year to menopause symptoms.

WAYS IN ・ 連携の形

Four doors, one platform

OPERATORS Hotels, ryokan, spas, longevity studios — **one system, one room.**

MAKERS Homes, hotel rooms, furniture, cars — **their product, our engine inside.**

RESEARCH Ovarian aging and light in tissue — **a consortium role.**

INVESTORS Seed extension, €700k soft cap — **one place for a Japanese strategic.**

MEET US IN JAPAN ・ 日本でお会いしましょう

Osaka 2–5 Oct ・ BioJapan Yokohama 7–8 Oct ・ Tokyo until 10 Oct

Company records, Sep 2026; revenue figures unaudited. Partnership models are proposals; scope and terms are agreed per project.

Japan is the most concentrated demand point for female-aging technology.

The most-aged society in the world: more than 29% of people are 65 or older. Women live longest here — and live the longest stretch with limits.

世界で最も高齢化が進む日本では、女性の平均寿命と健康寿命の差が11.6年あります。

11.6 yrs

lived with limits in daily life

Japanese women live to 87.1 and stay healthy to 75.5.



10.1 M

women aged 45–55


The menopause decade: in Japan it arrives at around 50.



¥1.9 tn

lost every year to menopause symptoms

Economic loss, not market size — of ¥3.4 tn lost to women's health issues overall.



1 in 8

babies born via assisted reproduction

550,000+ ART cycles a year — covered by public insurance since April 2022.



Tailwinds. Integrated Center for Women's Health (NCCHD) opened in 2024 · femtech & femcare market ≈ ¥80 bn (2024, industry estimate).


For a partner: the market where the need is largest, and where our platform is not yet running — the first partners define how it arrives.

Sources: MHLW life tables and healthy life expectancy (2022) · Statistics Bureau of Japan (population 1 Oct 2024; share aged 65+) · METI, women's health issues (Feb 2024) · JSOG ART registry (2024 data).

Light in, cell energy out. Four scales, one chain.

Red and near-infrared light travels from the skin to one enzyme in the mitochondria. There it is absorbed — and in lab studies, cells make more ATP, their energy currency.

赤色光・近赤外光は皮膚から組織に入り、ミトコンドリアの酵素（シトクロムcオキシダーゼ）に吸収されると考えられています。



01

Into tissue

Red is absorbed within 1–2 mm.
Near-infrared passes 2–5 mm, into deeper tissue.

02

Into the cell

It reaches the mitochondria, the cell's power plants. Egg cells carry ten times more than most cells.

03

Into the mitochondrion

Its folded inner membrane carries the respiratory chain — five enzyme complexes in a row.

04

At complex IV


Cytochrome c oxidase absorbs the light. The proton gradient grows; ATP synthase makes more ATP.

Schematic, not to scale. Complex IV involvement is supported in experimental settings; other pathways also contribute. Sources: Shimojo, J Biomed Opt 2020 · Wong-Riley, J Biol Chem 2005 · Wai, Biol Reprod 2010 · Hamblin, AIMS Biophys 2017.

More light is not better. The right dose is.

Cells answer light with a biphasic curve: nothing below a threshold, a response inside a window, less above it. The engineering problem is to land inside the window — every session.

光が多ければ良いわけではありません。適切なドーズが重要です。



BELOW

Too little does nothing.

Under the threshold, cells do not respond — the common failure of weak or distant panels.

WINDOW

Enough, and cells respond.

Energy metabolism rises inside a defined range of dose.

ABOVE

Too much does less.

Past the window the effect fades, then inhibits.

OptimalDose™ sets each programme inside the window and caps it. The product fixes the distance, so the dose holds — and every connected session is logged.

Schematic curve, not measured data; the window's position depends on tissue, wavelength and endpoint. Sources: Huang et al., Dose-Response 2009 · Huang et al., Dose-Response 2011.

One light engine, from the clinic to the home.

Three ways to use the same technology: a full-body system for operators, a wearable for women at home, and the engine for partners to build in.

施設用の全身システムと女性向けの家庭用機器を提供し、光エンジンのライセンス供与も準備しています。



FOR OPERATORS · CLINICS, LONGEVITY CENTRES, SPAS & HOTELS

Redgeivity Master

Full-body system, co-developed with Biogen. Sold with a monthly software licence.

- Dose set and capped
- Sessions logged when connected
- Guests start at the kiosk
- Staff app and dashboard
- Ready for the spa menu
- 4,608 LEDs




FOR HER · AT HOME

Luminous Kini

Our female-health device: worn on the lower abdomen, 660 + 850 nm. Plus Essential & Pro home panels.

- No drug, no needle
- Same distance, on the skin
- 20 minutes, then off
- No UV: red + NIR
- Plan from our science team
- 5,000+ home devices sold



Now licensing

FOR PARTNERS · LICENSING

The light engine

CellLight™ + OptimalDose™ as one module for other products.

- Light + dose logic, one module
- Rooms, beds and furniture
- Vehicles: first project
- Specs and test data


Product facts: company product sheets · Luminous Kini 660 + 850 nm, 20-minute timer · Redgeivity Master co-developed with Biogen Group · 17 systems: management count, Sep 2026. Images: Redgeivity Master installations, Luminous Labs.

Out of the lab, into the clinic — and into the market.

稼働台数は約1年半で7台から17台へ。創業以来の売上は約250万ユーロ、2025年は前年比約2.6倍（社内集計・未監査）。

REDGEVITY MASTER SYSTEMS INSTALLED

17
systems in 5 countries
AT · DE · CH · UK · IE



BIOGENA

Strategic investor, co-developer
and operator. Listed in Vienna,
September 2026.

≈ €2.5M

revenue since 2021

up 2.6× from 2024 to 2025 · ≈ €1M
expected in 2026

5,000+

home devices sold

Luminous Kini and home panels

13,000+

sessions logged

on connected Redgevity Master systems

WHERE OUR LIGHT RUNS

Biogena Plazas & Longevity Labs
Vienna · Salzburg · London

House of IKKI
Vienna

Waldhof Fuschlsee
Salzburg region

RedUp
Munich

PulseHealth
Dublin

Le Grand Bellevue
Gstaad

KIWI · Fertisuisse
clinic partners, AT · CH

Sources: company records (system count, Sep 2026; fleet log, Aug 2026) · revenue: management figures, unaudited, approx.; 2026 figure is a forecast · Biogena Group listing in Vienna, 10 Sep 2026.

Built with people who operate, invest and research.

Our European relationships connect the product to professional use, clinical questions and the wider healthspan community.



STRATEGIC INVESTOR &
CO-DEVELOPER

Biogen Group

Investment, Redgevity Master development and operating locations. Listed in Vienna, Sep 2026.

LE GRAND BELLEVUE

HOSPITALITY PARTNER

Le Grand Bellevue · Le Grand Spa

Sessions and the Luminous Kini on the spa's own menu, Gstaad.



CLINICAL RESEARCH

Das Kinderwunsch Institut Schenk

Austrian clinic observations; observational study since Aug 2026.



CLINICAL RESEARCH

Fertisuisse

Swiss clinical collaboration and longitudinal case follow-up.



RESEARCH PARTNER

Politecnico di Milano

Prof. Antonio Pifferi's team: measuring light in tissue (PhotonHub Phactory project, funded).



CONFERENCE SHOWCASE

Longevity Investors Conference

Gstaad: the only non-drug, non-invasive startup showcased; continuing involvement.



SUMMIT PARTICIPATION

Hevolution · Global Healthspan Summit

Invited participation from the inaugural summit.

MEDIA

Press

Interviews and articles in Austrian business and startup media.

SUPPORTED BY

FFG · SFG · Science Park Graz · Silicon Alps · Human Technology Styria

IN JAPAN

GO TOKYO 2026 with GIN and Advantage Austria · Osaka · Yokohama · Tokyo

FEATURED IN **Forbes** **brutkasten**

Relationship roles as of Sep 2026; company records and founder confirmation. Event participation and media do not imply investment or scientific endorsement. Sources: [P2], [P3], [M2], [M3].

The team that built it, sold it and installed it — in five countries.

Engineering, science and sales under one roof in Graz, with the research and clinical partners who test the work.

開発・研究・販売を一つのチームで担い、5カ国に導入してきました。



Barbara Sekulovska

CEO & CO-FOUNDER

7 years in photobiomodulation and women's health research. Strategy, finance and partnerships — the Biogena relationship and this round.

Thomas Lechner

CTO & CO-FOUNDER

Lighting engineer, 10 years in LED hardware. Architect of the CellLight™ engine.

Sarah Wetzlmair

CHIEF SCIENCE

PBM research; built the 9,452-paper database behind OptimalDose™.

Angelo Jakup-Sekulovski

CHIEF SALES

12 years in health retail. B2B sales and roll-out — all 17 Redgevity Master installations.

RESEARCH & CLINICAL NETWORK

Politecnico di Milano — Prof. Antonio Pifferi, tissue optics · PhotonHub Phactory project, Horizon Europe · Das Kinderwunsch Institut Schenk · Fertilisuisse · Biogena Group, investor and co-developer

The moat is not the LED. It is the chain behind it.


9,452 papers, turned into dosing logic and protocols, run on a connected fleet that logs every session — and clinics that measure.

私たちの強みはLEDではなく、研究・ドーズ設計・運用データのつながりです。

	Typical red-light panels	Clinic lasers & medical PBM	Pharma & hormones	Luminous Labs
The dose	sold by power at the panel	set by a clinician	a prescribed drug dose	set and capped; logged on connected systems; measured in tissue next
Distance to the body	you choose, so the dose varies	a handpiece, in the clinic	—	fixed position: lying in the Redgevity Master, the Luminous Kini on the skin
Evidence	rarely studied as sold	published, device by device	established for approved uses	9,452-paper database, clinic observations, controlled study next
Route in Japan	consumer electronics	medical-device approval	drug approval	wellness first; medical claims only on a separate route

Typical cases; individual products differ.

PARTNERS & VALIDATION

 BIOGENA KINDErwunsch INSTITUTE fertilisuisse

Investor, co-developer, operator · fertility clinic, Austria
· fertility clinics, Switzerland

RESEARCH

- Politecnico di Milano: measuring light in tissue (PhotonHub Phactory, Horizon Europe — funded)
- FFG Eureka Globalstars Japan: open for a Japanese co-applicant
- XPRIZE Ovarian Health: entry in preparation

RECOGNITION & IP

- Longevity Investors Conference, Gstaad: the only non-drug, non-invasive startup showcased
- CellLight™: patent pending (AT A65/2024)

Sources: Luminous Labs PBM research database (9,452 papers) · fleet records (Aug 2026) · CellLight™ patent application AT A65/2024 (pending) · PhotonHub Phactory innovation project with Politecnico di Milano, accepted Sep 2026 · FFG Eureka Globalstars Japan call (Austria–Japan R&D).

Pick your door. Each one has a first step we can take this quarter.



Operators & hospitality

Ryokan, hotel spas, longevity and recovery studios.

YOU GET

A Redgevity Master with guest kiosk, staff app and a dose that is set and capped; a joint review of the session log.

YOU BRING

The room, the guests and the operating team.

FIRST STEP

One system, one room.



Makers & integrators

Homes, hotel rooms, beds, furniture and vehicles.

YOU GET

CellLight™ + OptimalDose™ as one licensable module, with specifications and test data.

YOU BRING

Product architecture, industrialisation, your brand and channels.

FIRST STEP

One application, evaluated together.



Research & clinics

Ovarian aging, the uterine lining, light in tissue.

YOU GET

Devices, dosimetry know-how, our 9,452-paper database and European clinic partners.

YOU BRING

Investigators, patient populations, ethics and endpoints.

FIRST STEP

A co-applicant role — FFG Eureka Globalstars Japan, with a Japanese partner.



Strategic investors

The role Biogen plays in Europe: invest, co-develop, operate.

YOU GET

Equity in Luminous Labs FlexCo and a seat in building Japan.

YOU BRING

Capital, market access and an operating channel.

FIRST STEP

Reserve an allocation by 30 Nov.

Proposed collaboration models. Territory, exclusivity, fees and supply commitments are agreed for the selected project. Research results and commercial wellness claims stay separate.

Wellness & hospitality → built-environment integration → reproductive-aging R&D.

ウェルネス・宿泊施設から始め、住まい・客室・車への組み込み、卵巣エイジングの共同研究へと三段階で進めます。

MOVE 1 · START

Wellness & hospitality

Ryokan, hotel spas, longevity and recovery studios in Kansai and Tokyo — the kinds of venues where our systems run in Europe.

FOR A JAPANESE PARTNER

A system already running in Europe, with guest kiosk and staff app; a joint review of the session log.

First step: one system, one room.

MOVE 2 · BUILD IN

Built-environment integration

The light engine inside homes, hotel rooms and cars, with Japanese partners, under their brand.

FOR A JAPANESE PARTNER

A licensable engine with dose control, specifications and test data.

Their product, our engine inside.

MOVE 3 · RESEARCH

Reproductive-aging R&D

From BioJapan, Yokohama, 7–8 Oct: research partners on ovarian aging and on measuring light in tissue.

FOR A JAPANESE PARTNER

A consortium role, dosimetry know-how and our 9,452-paper database.

Medical use only on its own
Japanese route.

WARM NETWORK

Biogena, GIN and Advantage Austria. Biogena Group: our strategic investor and operating partner in Europe. GIN and Advantage Austria: the GO TOKYO 2026 programme. Meetings in Osaka, Yokohama and Tokyo, 2–10 October.

REGULATORY

CE-marked wellness devices in Europe. In Japan: wellness first — classification, PSE and labelling confirmed with a Japanese importer and a regulatory specialist before the first system ships; medical claims only on a separate route.

Sources: GO TOKYO 2026 programme (GIN, Advantage Austria) · company meeting plan, 2–10 Oct 2026.

Define the use. Build the route around it.

Every partnership starts with the intended use, the customer and the requirements of the Japanese market. Three routes — kept deliberately separate.

01 · NOW	02 · WITH A MAKER	03 · SEPARATE PROGRAMME
Wellness products & services	Technology integration	Medical development
CLAIMA non-medical wellness experience	CLAIMSet by the final product owner	CLAIMOne specific indication at a time
CHECKSPSE product safety · labelling · advertising wording	CHECKSClassification review, including software’s role in dosing	CHECKSPMD Act authorisation, reviewed by PMDA
WHO LEADS A Japanese importer with a regulatory specialist	WHO LEADS The product owner	WHO LEADS Sponsor with clinical partners
WE SUPPLY Systems, devices and guest-facing wording for review	WE SUPPLY Specifications, change records and test evidence	WE SUPPLY Dosimetry, device records and protocols
FIRST PRODUCT Redgevity Master in venues · Luminous Kini at home	FIRST PRODUCT Their product, our engine inside	FIRST PRODUCT Evidence first: controlled studies

WHY THREE ROUTES

A wellness claim and a medical programme on the same product put both at risk. We keep them apart from the first day — so each partner knows exactly which rules apply to what they sell.

Proposed approach; final product, claims, evidence and local obligations determine the route. Sources: [J2] PMDA, regulations and approval/certification of medical devices · [M1] PMD Act framework.

From a first meeting to a first system — in four clear steps.

We keep the first project small, well-defined and easy to judge. Expansion follows results, not promises.

1

2–10 OCT 2026

Meet

Osaka, Yokohama or Tokyo.
We bring the Luminous Kini,
the session data and the
reference sites.

2

THE WEEKS AFTER

Scope

Pick the room, the application
or the research question.
Agree owners, success
measures and the
commercial frame.

3

BEFORE ANYTHING SHIPS

Review

Classification, PSE, labelling
and every marketing sentence
— with a Japanese importer
and a regulatory specialist.

4

FIRST SYSTEM IN JAPAN

Launch

One system, one room — or
one prototype, one study.
A joint review decides the
next step.

WHAT YOU CAN INSPECT ON DAY ONE

- A system running in Europe — visit Vienna, Salzburg, Gstaad or London
- The session log: 13,000+ logged sessions across the fleet
- Product sheets, engine specifications and test data
- The clinic observations and our 9,452-paper research database

WHY START NOW

2–10 Oct

founders in Japan

30 Nov

round allocations close

The founders are in Japan 2–10 October. The first Redgevity Master in Japan is funded by the current round — the partners we meet in October shape where and how it runs.

Indicative sequence, not a committed schedule. Regulatory steps depend on product, intended use and claims.

We're ready for the next step.

Five years, one Austrian biotech going to Japan. Tell us which door fits — we'll bring the first step.

10月10日まで、日本で皆さまとお会いできます。



MEET US IN JAPAN ・ 日本でお会いしましょう

2 Oct **Osaka** · LifeTech+ Startup Night

5 Oct **Osaka** · EU-Japan Partnering

7–8 Oct **Yokohama** · BioJapan

9 Oct **Tokyo** · TechBIZKON X: LifeTECH+

Book a meeting in Osaka, Yokohama or Tokyo.

Barbara and Thomas are in Japan until 10 October 2026.



Thomas Lechner · co-founder & CTO

thomas@luminouslabs.health

+43 664 4603640 · luminouslabs.health/japan

Research database:

luminouslabs.health/database

Luminous Labs FlexCo · Graz, Austria · founded 2021 · Science Park Graz ·
Silicon Alps · Human Technology Styria

Every number, traceable.

Published literature, market data and company records behind this document. The full research database and data room are available on request.

PUBLISHED RESEARCH

[1]	Wong-Riley et al. (2005). Neuronal PBM and cytochrome c oxidase. J Biol Chem 280:4761–4771. DOI 10.1074/jbc.M409650200
[2]	Quirk & Whelan (2021). Isolated cytochrome c oxidase experiments. Photobiomodul Photomed Laser Surg 39:463–470. DOI 10.1089/photob.2020.4978
[3]	Pope & Denton (2023). 808 nm effects on mitochondrial electron-transport complexes. Mitochondrion 68:15–24. DOI 10.1016/j.mito.2022.11.002
[4]	Fear et al. (2023). ATP kinetics by ³¹ P-MRS after 670 nm PBM in older adults. Aging Cell 22:e14005. DOI 10.1111/accel.14005
[5]	He et al. (2024). PBM ameliorates ovarian aging via oxidative stress, inflammation and mitochondrial function. J Photochem Photobiol B 260:113024. DOI 10.1016/j.jphotobiol.2024.113024
[6]	Su et al. (2026). 630 nm LED phototherapy and ovarian function in advanced reproductive age. Bioeng Transl Med 11:e70117. DOI 10.1002/btm2.70117
[7]	Jafarabadi, Farbod & Shariat (2024). LLLT for IVF outcomes in recurrent implantation failure: an RCT. J Lasers Med Sci 15:e15. DOI 10.34172/jlms.2024.15
[10]	Stigliani et al. (2026). Near-infrared PBM and human oocyte rescue in vitro maturation. J Photochem Photobiol B 279:113452. DOI 10.1016/j.jphotobiol.2026.113452
[H4]	López-Otín et al. (2023). Hallmarks of aging: an expanding universe. Cell 186:243–278. DOI 10.1016/j.cell.2022.11.001
[D]	Huang et al., Dose-Response 2009 and 2011 (biphasic dose response) · Shimojo et al., J Biomed Opt 2020 (tissue optics, Osaka University) · Wai et al., Biol Reprod 2010.

JAPAN MARKET, BIOLOGY & REGULATION

[J]	MHLW life tables & healthy life expectancy 2022 · Statistics Bureau of Japan, 1 Oct 2024 · METI, women's health issues, Feb 2024 · JSOG ART registry 2023–2024.
[0]	Faddy, Hum Reprod 1992 · ACOG/ASRM 2014 · Garrison, Buck Institute 2023 (≈2.5×, expert estimate) · El Khoudary, Circulation 2020 · Greendale (SWAN) 2012 · Mosconi, PLoS ONE 2017.
[J2]	PMDA. Regulations and approval/certification of medical devices. pmda.go.jp
[M1]	Japan PMD Act and regulatory framework, PMDA overview and linked legislation.

COMPANY & PARTNERS

[C1]	Luminous Labs / Fertiluisse / Kinderwunsch Institut Schenk. From first cases to scalable evidence. Company whitepaper, 30 Jan 2026; unpublished.
[P1]	Luminous Labs. The Luminous Protocol: how we build a plan that's actually yours. 13 Aug 2026.
[P2]	Le Grand Bellevue. Le Grand Spa menu, winter 2025/26, p. 5.
[P3]	Luminous Labs. Biogena investment and partnership announcement, 13 Oct 2024.
[M2]	Forbes Austria and brutkasten, 2023.
[M3]	
[R]	Company records: 17 systems (Sep 2026); 13,000+ logged sessions (Aug 2026); 5,000+ devices; revenue ≈ €2.5M since 2021, unaudited; CellLight™ AT A65/2024 (pending).

A focused selection, current to Sep 2026. Published research uses other groups' devices and protocols; it is not evidence of efficacy for Luminous Labs devices, which are CE-marked wellness devices. Explore the research database: luminouslabs.health/database